Drug Insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation
Gérard Helft*, Martine Gilard, Claude Le Feuvre and Azfar G Zaman
Correspondence *Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Boulevard de l'Hôpital, 75013 Paris, France
Email gerard.helft@psl.aphp.fr
The current treatment for patients receiving coronary stents is dual antiplatelet therapy. Approximately 5% of these patients, however, require long-term anticoagulation because of an underlying chronic medical therapy and, theoretically, should receive triple therapy, which increases bleeding risk. Here, Helft et al. critically appraise the available literature concerning antithrombotic therapy and make recommendations for antiplatelet therapy following revascularization in the small subset of patients already receiving anticoagulation.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
